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Abstract 26 
Background 27 
Anticholinergic burden is associated with poorer cognitive and functional outcomes in people 28 
with dementia. However, the impact of anticholinergics on significant adverse outcomes such as 29 
stroke has not been studied previously.  30 
 31 
Objective 32 
To investigate the association between total anticholinergic cognitive burden (ACB) and risk of 33 
stroke and death in people with different dementia subtypes. 34 
 35 
Methods 36 
This was a cohort study of 39107 people with dementia and no prior history of stroke registered 37 
in the Swedish Dementia Registry (SveDem) from 2008 – 2014. Data were extracted from the 38 
Swedish Prescribed Drug Register, the Swedish National Patient Register and the Swedish Total 39 
Population Register. Competing risk regression models were used to compute hazard ratios (HRs) 40 
and 95% confidence intervals (CIs) for the association between time-varying ACB score and risk 41 
of stroke and all-cause mortality.  42 
 43 
Results 44 
During a mean follow-up period of 2.31 (standard deviation 1.66) years, 11224 (28.7%) 45 
individuals had a stroke or died. Compared with non-users of anticholinergic medications, ACB 46 
score of 1 (HR 1.09, 95%CI 1.04 – 1.14) and ACB score of ≥2 (HR 1.20, 95%CI 1.14 – 1.26) 47 
increased the risk of developing the composite outcome of stroke and death. When stratifying by 48 
dementia disorder, the association remained significant in Alzheimer’s disease, mixed dementia 49 
and vascular dementia. 50 
 51 
Conclusions 52 
The use of anticholinergic medicines may be associated with an increased risk of stroke and death 53 
in people with dementia. A dose-response relationship was observed. Careful consideration 54 
should be made when prescribing medications with anticholinergic properties to people with 55 
dementia. 56 
 57 
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Introduction 61 
Medications with anticholinergic properties are commonly used in older people for a range of 62 
therapeutic indications. Anticholinergic burden, the cumulative effect of taking multiple 63 
medicines with anticholinergic properties, has been found to be associated with significant 64 
adverse effects on cognitive and physical function in older people; however, there is limited 65 
evidence for mortality and cerebrovascular outcomes.[1-5] A meta-analysis concluded that every 66 
unit increase in the anticholinergic cognitive burden (ACB) scale was associated with a doubling 67 
in odds of all-cause mortality (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.82 – 68 
2.33).[3] A study in the general older population reported a significant dose-response association 69 
between total ACB score and mortality and cardiovascular outcomes, including stroke.[6]  70 
 71 
People with dementia have been shown to be high users of medications with anticholinergic 72 
properties.[7] Whilst the negative effects of anticholinergic medications on cognition and 73 
dementia progression have been studied extensively,[8] few studies have explored the impact of 74 
anticholinergics on other important adverse outcomes including stroke and mortality in 75 
individuals with dementia. There is some evidence to suggest that there is an increased risk of 76 
mortality with the use of anticholinergic medications in people with dementia; however, findings 77 
are inconsistent.[9-11] Additionally, these studies are limited by small sample sizes, short 78 
durations of follow-up and failure to differentiate between different subtypes of dementia which 79 
may be important regarding underlying mechanisms of the disease. To date, the association 80 
between anticholinergic burden and stroke risk in people with dementia has not been 81 
investigated. This is of importance as people with dementia are at a two-fold greater risk of stroke 82 
compared to those without dementia.[12]  83 
 84 
The aim of this study was to investigate the association between anticholinergic burden with 85 
stroke and death in people with dementia, and whether this association varied by type of 86 
dementia disorder. 87 
 88 
Methods 89 
Study population 90 
This was a cohort study based on individuals registered at the time of the dementia diagnosis in 91 
the Swedish Dementia Registry (SveDem, www.svedem.se) from 2008 to 2014. The Swedish 92 
Dementia Registry (SveDem) is a national quality registry for monitoring the diagnosis, treatment 93 
and care of people with dementia in Sweden.[13] It covers 100% of memory clinics and 75% of 94 
primary care units in Sweden. It included a total of 48766 individuals with newly diagnosed 95 
dementia from 2008 to 2014. To be eligible for inclusion in this study, participants needed to 96 
have no prior history of stroke and complete baseline data. After excluding those with previous 97 
stroke (n=6191, 12.7%) and missing data (n=3468, 7.1%), a total of 39107 people were included 98 
in the analyses.  99 
 100 
Data sources 101 
Information on dispensed drugs was extracted from the Swedish Prescribed Drug Register. All 102 
prescriptions dispensed by Swedish pharmacies are captured in this register together with unique 103 
patient identifiers. The National Board of Health and Welfare maintains this register and 104 
coverage is >99%.[14] All drugs are classified according to the Anatomical Therapeutic 105 
Chemical (ATC) code. To be considered a user of a medication, participants had to have at least 3 106 
prescriptions or 20 unit doses dispensed in the previous year.  107 
Information on medical diagnoses at baseline and during follow-up were extracted from the 108 
Swedish National Patient Register. This register contains prospectively collected data from all 109 
inpatient and specialized outpatient visits in Sweden and is maintained by the Swedish National 110 
Board of Health and Welfare. The coverage of inpatient discharges is >99%.[15] The medical 111 
diagnoses of all individuals are classified according to the International Classification of 112 
Diseases, Tenth Revision, (ICD-10). Information on all-cause mortality were extracted from the 113 
Swedish Total Population Register. This register is maintained by Statistics Sweden and covers 114 
100% of all deaths in Sweden.[16] 115 
 116 
Anticholinergic exposure measure 117 
Anticholinergic exposure was defined using the Anticholinergic Cognitive Burden scale 118 
(ACB).[17, 18] The ACB scale assigns a score of zero for medications with no known 119 
anticholinergic activity, one for medication with possible anticholinergic properties, two for 120 
medications with definite clinical anticholinergic properties, and three for medications with 121 
definite anticholinergic properties that may cause delirium (Suplementary Table 1). The ACB 122 
scale is the most frequently validated tool for assessing the effect of anticholinergic medications 123 
on adverse outcomes.[4] A total ACB score was calculated for each patient annually by adding 124 
the individual scores of different medications in a patient’s prescribed regimen. Annual total 125 
ACB score was analyzed as a time-varying variable i.e. the most recent score prior to outcome or 126 
study end was used in the analysis. Scores were further categorized into 0, 1 or ≥2.  127 
 128 
Outcomes 129 
The primary outcome was the composite of first stroke (any) and all-cause mortality. Secondary 130 
outcomes were death, any stroke and ischemic stroke. Stroke was defined as first occurrence of 131 
ICD-10 codes I61, I63 or I64. Ischemic stroke was defined as first occurrence of ICD-10 code 132 
I63. 133 
 134 
Confounders 135 
Demographic data at baseline were obtained from SveDem and included age, sex, Mini-mental 136 
state examination (MMSE),[19] living situation (institutionalized, living alone or living at home 137 
with a co-resident), home care use and dementia disorder.[13] Dementia diagnoses were made 138 
according to ICD-10 criteria[20] and coded as Alzheimer’s disease (AD), vascular dementia, 139 
mixed dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s disease 140 
dementia (PDD), unspecified dementia and other dementia types. Charlson comorbidity index 141 
was used as a measure of the number and severity of comorbid conditions at baseline.[21] 142 
Antidementia drugs at baseline were defined as ATC code N06D.  143 
 144 
Statistical analysis 145 
Analysis of variance and chi square statistics were used to compare participant baseline 146 
characteristics according to ACB score. Baseline was defined as the date of dementia diagnosis. 147 
Time-dependent Cox proportional hazards models were used to estimate hazard ratios (HRs) and 148 
95% confidence intervals (CI) for the association between time-varying annual total ACB score 149 
and the primary outcome and all-cause death. Adjusted subdistribution HRs (sHRs) and 95% CIs 150 
were calculated for the occurrence of any incident stroke and ischemic stroke, adjusting for 151 
mortality as a competing risk. All multivariable models were adjusted for age, sex, Charlson 152 
Comorbidity Index, living situation, home care, dementia disorder, MMSE and use of 153 
antidementia drugs at baseline. Survival time was defined as the time from date of dementia 154 
diagnosis (index date) to date of first stroke, death or 31 December 2014, whichever came first. 155 
Subgroup analyses according to dementia disorder subtype was performed. To explore whether 156 
the association between anticholinergic burden and stroke and death was due to long-term effects, 157 
we also performed a sensitivity analysis using baseline total ACB score as the exposure i.e. total 158 
ACB score calculated based on medication use in the year preceding dementia diagnosis. 159 
 160 
Ethical considerations 161 
All patients in SveDem were informed about their participation in the registry and had the right to decline 162 
participation or withdraw consent. This study was approved by the regional human ethics committee 163 
in Stockholm (approval number 2015/743-31/4). Data were coded and anonymized before 164 
statistical analyses. 165 
 166 
Results  167 
Study population and characteristics 168 
The study cohort consisted of 39107 people with a mean age of 79.9 (standard deviation [SD], 169 
7.90) years with the majority being female (60.7%). At baseline, 24573 (62.8%) participants had 170 
an ACB score of 0, 8239 (21.1%) a score of 1 and 6295 (16.1%) a score of ≥2. The mean ACB 171 
score at baseline was 0.67 (range: 0 to 12) and the mean time-varying ACB score was 0.73 172 
(range: 0 to 12). The most commonly used drugs contributing to ACB score ≥1 were metoprolol 173 
(C07AB02) (39.6%), furosemide (C03AC01) (25.0%), and warfarin (B01AA03) (13.4%). 174 
Participants with higher ACB scores were more likely to be older, institionalized, receive home 175 
care, have a greater number of comorbidities, take a higher number of drugs and be less likely to 176 
use antidementia drugs. Whilst they were less likely to have AD, those with higher ACB scores 177 
were more likely to be diagnosed with other dementia subtypes including mixed dementia, 178 
vascular dementia and PDD. Detailed demographic information is reported in Table 1. 179 
 180 
Risk of death and stroke in the dementia cohort 181 
During the follow-up period (mean [SD] 2.31 [1.66] years), 11224 (28.7%) individuals had a 182 
stroke or died. Crude incidence rates for the primary outcome of the composite of stroke and 183 
death were higher in those with higher ACB score (111, 130 and 155/1000 person-years, for ACB 184 
scores 0, 1 and ≥2, respectively) (Table 2). The individual crude incidence rates for death, stroke 185 
and ischemic stroke similarly increased with increasing ACB scores.  186 
 187 
After adjusting for potential confounders, time-varying ACB score was associated with an 188 
increased risk of developing the primary outcome (HR 1.05, 95%CI 1.03 – 1.06) (Table 3). When 189 
categorizing time-varying ACB score, ACB score of 1 (HR 1.09, 95%CI 1.04 – 1.14) and ACB 190 
score of ≥2 (HR 1.20, 95%CI 1.14 – 1.26) were associated with the primary outcome, indicating 191 
a dose-response relationship. Similar findings were found for the outcome of death with 192 
continuous ACB score (HR 1.04, 95%CI 1.02 – 1.06), and categorized ACB score of 1 (HR 1.09, 193 
95%CI 1.04 – 1.14) and ACB score of ≥2 (HR 1.18, 95%CI 1.12 – 1.24) associated with an 194 
increased risk of death. A significant association was found between ACB score and any stroke 195 
(sHR 1.11, 95%CI 1.07 – 1.15) and ischemic stroke (sHR 1.06, 95%CI 1.02 – 1.11); however, 196 
this remained significant only for higher ACB score (≥2) (any stroke: sHR 1.13, 95%CI 1.00 – 197 
1.27; ischemic stroke: sHR 1.15, 95%CI 1.00 – 1.31). Sensitivity analyses using baseline ACB 198 
score produced similar results (Supplementary Table 2). 199 
 200 
Table 4 reports the hazard ratios for the association between time-varying ACB scores and the 201 
primary outcome, stratified by dementia disorder. Time-varying ACB score was associated with 202 
the primary outcome for patients with AD (HR 1.08, 95%CI 1.05 – 1.12), mixed dementia (HR 203 
1.05, 95%CI 1.01 – 1.09), vascular dementia (HR 1.04, 95%CI 1.01 – 1.08) and unspecified 204 
dementia (HR 1.06, 95%CI 1.02 – 1.09). When categorizing ACB score, ACB score of ≥2 205 
remained significantly associated with the primary outcome for these dementia disorders. 206 
Compared with an ACB score of 0, an ACB score of 1 was found to be associated with a reduced 207 
risk of developing the primary outcome in patients with Parkinsons disease dementia (HR 0.53, 208 
95%CI 0.34 – 0.83). Sensitivity analyses found no significant association between baseline ACB 209 
score and the primary outcome after stratifying by dementia disorder, except for people with AD 210 
or unspecified dementia with ACB score of ≥2 (Supplementary Table 3). 211 
 212 
Discussion 213 
Our study found that higher total anticholinergic burden was associated with an increased risk of 214 
all-cause mortality and stroke in people with dementia, compared with those with lower or no 215 
anticholinergic burden. This association remained significant in those with AD, mixed dementia 216 
and vascular dementia after stratifying by dementia disorder.  217 
 218 
Previous studies of anticholinergic burden and mortality in people with dementia have shown 219 
mixed findings. A recent study by Cross et al. reported that time-dependent ACB scores were 220 
associated with mortality (adjusted HR 1.18, 95% CI 1.02 – 1.32) in older people with cognitive 221 
impairment attending Australian memory clinics. Another study by Gnijdic et al. reported that 222 
baseline anticholinergic burden, measured using the Drug Burden Index (DBI), was associated 223 
with one-year mortality (adjusted HR 1.21, 95%CI 1.09 – 1.33) in people with AD in Finland. 224 
Conversely, other studies have found no association between the use of medications with 225 
anticholinergic properties and mortality in people with dementia.[11, 22]  226 
 227 
To date, there has been limited research into the association between anticholinergic burden and 228 
stroke risk in people with dementia. However, there is evidence to suggest a possible association 229 
between anticholinergics and cardiovascular and cerebrovascular outcomes in the general older 230 
population.[23] Higher ACB scores have been found to be associated with both mortality and 231 
cardiovascular disease incidence, including stroke.[6, 24] Additionally, higher ACB scores in 232 
older patients with cardiovascular disease has been shown to increase risk of hospitalization and 233 
mortality.[25, 26]   234 
 235 
There are a few potential mechanisms which may explain why anticholinergic medications may 236 
increase mortality and incidence of stroke. It has been suggested that anticholinergic medications 237 
have pro-arrhythmic and pro-ischaemic properties.[27, 28] Anticholinergics may have an effect 238 
on cardiovascular homeostasis, producing tachycardia and orthostatic hypotension, both of which 239 
may be associated with an increased risk for ischemic stroke. Additionally, given the cholinergic 240 
system has a role in regulating immune response, another potential mechanism may be through 241 
immunomodulation. Anticholinergics may inhibit immune system processes leading to 242 
inflammatory reponses and an increased risk of stroke and mortality in people with dementia with 243 
underlying risk factors.[29] 244 
 245 
To our knowledge, no previous studies have investigated the impact of anticholinergic 246 
medications across different dementia subtypes. Our study found that the regular use of definite 247 
anticholinergics (ACB score of ≥2) was associated with increased risk of stroke and death in 248 
those dementia subtypes with a probable underlying vascular component (AD, mixed dementia 249 
and vascular dementia). This may indicate these patients are inherently at risk of stroke and early 250 
mortality and that the use of anticholinergic medications may compound this. Alternatively, 251 
several cardiovascular medications, such as diuretics, antihypertensives and antithrombotics, 252 
have anticholinergic properties, and these drugs were the main contributors to ACB score in our 253 
study population. It is thus possible that the use of these medications is reflective of underlying 254 
vascular problems that can increase risk of stroke and death in this population.  255 
 256 
The use of anticholinergics in people with dementia is questionable, given their negative impact 257 
on cognition.[5] The use of anticholinergics in conjuction with antidementia drugs, such as 258 
acetylcholinesterase inhibitors, appears counterintuitive given the conflicting mechanisms of 259 
actions of the two drug classes.[30] Acetylcholinesterase inhibitors have been shown to be 260 
associated with a reduced risk of stroke and mortality in people with Alzheimer’s disease and 261 
dementia.[31, 32] The use of anticholinergic medications may thus oppose these protective 262 
effects. Although partipants in our study were less likely to be using an acetylcholinesterase 263 
inhibitor if they had a higher ACB score, 40% of those with an ACB score of ≥2 were still 264 
concurrently prescribed an acetylcholinesterase inhibitor. 265 
 266 
Our study observed a linear dose-response relationship between anticholinergic burden and risk 267 
of mortality and stroke. In particular, we observed that the use of regular medications with 268 
definite anticholinergic properties (ACB score of ≥2) were associated with a 20% increase in the 269 
risk of stroke or death in people with dementia. This would be the equivalent of an individual 270 
taking a minimum of two ACB score 1 drugs e.g. metoprolol and venlafaxine together, or a single 271 
ACB score 2 or 3 drug e.g carbamazepine or oxybutynin. Given that several common 272 
medications used in older people contain anticholinergic properties, these findings highlight the 273 
care that should be made when considering the addition of a new medication in people with 274 
dementia. In particular, medications with anticholinergic properties should be carefully assessed 275 
for their risk versus benefit. Where possible, alternative medications with lower or no 276 
anticholinergic properties should be used instead. Additionally, medications used in people with 277 
dementia should be regularly reviewed to reduce anticholinergic burden where possible.[33]  278 
 279 
This study has several strengths and limitations. Strengths lie in the large, nationally 280 
representative cohort of individuals with dementia. Additionally, a wider range of dementia 281 
disorder subtypes were included compared with other studies, and we were able to make 282 
comparisons across different disorders. The ascertainment of medical diagnoses and medications 283 
employed the use of national registers that were complete and allowed for follow-up of 284 
individuals, thus eliminating any potential attrition or recall bias. Our medication exposure was 285 
time-dependent, taking into account the change in prescribing patterns that occur after dementia 286 
diagnosis and thus more accurately reflective of medication use at the time of event. We also 287 
supplemented this analysis using baseline medication exposure, to investigate long-term effects 288 
of anticholinergic burden. Although we know that medications were dispensed and collected 289 
from pharmacies, we did not explore the impact of medication adherence. Additionally, we did 290 
not consider non-prescription medications such as those obtained over-the-counter, nor 291 
medications used infrequently, thus we may have underestimated the effects. We cannot exclude 292 
the possibility of bias due to unmeasured confounding, in particular confounding by indication. 293 
Although we adjusted for a range of important covariates, it was not possible to control for all 294 
factors that may influence a physician’s decision to prescribe anticholinergic medications.  295 
 296 
Conclusion 297 
Our study found that total anticholinergic burden was associated with an increased risk of all-298 
cause mortality and incident stroke in people with dementia. A dose-response relationship was 299 
observed. This association remained significant in those with AD, mixed dementia and vascular 300 
dementia after stratifying by dementia disorder. Careful consideration should be made when 301 
prescribing medications with anticholinergic properties to people with dementia.  302 
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Table 1. Baseline characteristics according to ACB score 
 Total 
N = 39107 
0 
N = 24573 
1 
N = 8239 
≥2 
N = 6295 
p-value 
      
Female, n (%) 23735 (60.7) 15013 (61.1) 4955 (60.1) 3767 (59.8) 0.098 
MMSE, mean (SD) 20.43 (6.03) 20.47 (6.01) 20.41 (5.98) 20.29 (6.16) 0.08 
Age, mean (SD) 79.92 (7.90) 79.38 (8.14) 80.73 (7.35) 80.95 (7.45) <0.001 
Residency, n (%)      
At home with coresident 16617 (42.5) 10694 (43.5) 3350 (40.7) 2573 (40.9) <0.001 
At home alone 18976 (48.5) 11821 (48.1) 4129 (50.1) 3026 (48.1) 
Institutionalized 3514 (9.0) 2058 (8.4) 760 (9.2) 696 (11.1) 
Home care, n (%) 12076 (30.9) 7233 (29.4) 2593 (31.5) 2250 (35.7) <0.001 
Dementia disorder, n (%)      
AD 13269 (33.9) 9279 (37.8) 2462 (29.9) 1528 (24.3) <0.001 
Mixed dementia 7235 (20.7) 4262 (17.3) 1667 (20.2) 1306 (20.7) 
Vascular dementia 5967 (15.3) 3196 (13.0) 1474 (17.9) 1297 (20.6) 
Dementia with Lewy bodies 879 (2.2) 577 (2.3) 156 (1.9) 146 (2.3) 
Frontotemporal dementia 639 (1.6) 454 (1.8) 112 (1.4) 73 (1.2) 
Parkinson’s disease dementia 601 (1.5) 351 (1.4) 90 (1.1) 160 (2.5) 
Unspecified 9531 (24.4) 5816 (23.7) 2089 (25.4) 1626 (25.8) 
Other 986 (2.5) 638 (2.6) 189 (2.3) 159 (2.5) 
Charlson Comorbidity Index, mean (SD) 2.12 (1.63) 1.88 (1.45) 2.34 (1.70) 2.75 (1.96) <0.001 
Acute myocardial infarction 3948 (10.1) 1436 (5.8) 1241 (15.1) 1271 (20.2) <0.001 
Ischemic heart disease 7389 (18.9) 2758 (11.2) 2308 (28.0) 2323 (36.9) <0.001 
Atrial fibrillation 5800 (14.8) 1949 (7.9) 1671 (20.3) 2180 (34.6) <0.001 
Heart failure 3962 (10.1) 1289 (5.2) 1076 (13.1) 1597 (25.4) <0.001 
Diabetes 4957 (12.7) 2369 (9.6) 1327 (16.1) 1261 (20.0) <0.001 
Total number of drugs, mean, (SD) 6.53 (5.03) 4.61 (3.85) 8.52 (4.46) 11.41 (5.48) <0.001 
Use of any antidementia drugs, n (%) 19072 (48.8) 12672 (51.6) 3776 (45.8) 2624 (41.7) <0.001 
MMSE: Mini-mental state examination, AD: Alzheimer’s disease  
Table 2. Event rates for composite outcome, death, stroke and ischemic stroke by baseline ACB score 
 Total 
N = 39107 
0 
N = 24573 
1 
N = 8239 
≥2 
N = 6295 
p-value 
Composite outcomea, n (%) 11224 (28.7) 6607 (26.9) 2466 (29.9) 2151 (34.2) <0.001 
PY follow up 92646.40 59757.56 19015.07 13873.77  
Composite outcome/1000 PY 121.1 110.6 129.7 155.0  
Deaths, n (%) 10357 (26.5) 6091 (24.8) 2294 (27.8) 1972 (31.3) <0.001 
PY follow up 94908.81 61087.21 19478.26 14343.34  
Deaths/1000 PY 109 100.0 117.8 137.5  
Strokes, n (%) 1904 (4.9) 1071 (4.4) 419 (5.1) 414 (6.6) <0.001 
PY follow up 92646.40 59757.56 19015.07 13873.77  
Strokes/ 1000 PY 20.6 17.9 22.0 29.8  
Ischemic strokes, n(%) 1461 (3.7) 804 (3.3) 335 (4.1) 322 (5.1) <0.001 
PY follow up 93118.28 60045.94 19105.77 13966.57  
Ischemic strokes/1000 PY 15.7 13.4 17.5 23.1  
PY: person-years 
a. Composite of death or any stroke  
Table 3. Hazard ratios for the association between time-varying ACB score and stroke and death in people with dementia 
(N=39,107)  
 Composite stroke and 
death 
Death Stroke Ischemic stroke 
HRs (95% CI)a     
Continuous 1.05 (1.03 – 1.06)*** 1.04 (1.02 – 1.06)*** 1.11 (1.07 – 1.15)*** 1.06 (1.02 – 1.11)** 
Categorical     
0 (n=22919) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
1 (n=9184) 1.09 (1.04 – 1.14)** 1.09 (1.04 – 1.14)** 0.97 (0.86 – 1.08) 1.01 (0.89 – 1.15) 
≥2 (n=7004) 1.20 (1.14 – 1.26)*** 1.18 (1.12 – 1.24)*** 1.13 (1.00 – 1.27)* 1.15 (1.00 – 1.31)* 
a. Adjusted for age, sex, Charlson Comorbidity Index, institutionalisation, living alone, home care, Mini-Mental State 
Examination score and use of antidementia drugs at baseline 
b. Subdistribution hazard ratio 
*p <0.05 
**p<0.01 
***p<0.001 
  
Table 4. Association between time-varying ACB scores and composite of stroke and death by dementia disorder (N=39,107) 
 AD 
N = 13269 
MixedD 
N = 7235  
VaD 
N = 5967  
DLB 
N = 879 
FTD 
N = 639 
PDD 
N = 601 
Unspecified 
N = 9531 
Other 
N = 986 
HRs (95% 
CI)a 
        
Continuous 1.08 (1.05 – 
1.12)*** 
1.05 (1.01 – 
1.09)** 
1.04 (1.01 – 
1.08)* 
0.94 (0.86 – 
1.03) 
0.95 (0.85 – 
1.07) 
0.94 (0.86 – 
1.03) 
1.06 (1.02 – 
1.09)*** 
1.04 (0.95 – 
1.14) 
Categorical         
0 (n=22919) 1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1 (n=9184) 1.12 (1.02 – 
1.22)* 
1.04 (0.95 – 
1.15) 
1.10 (0.98 – 
1.22) 
1.04 (0.79 – 
1.37) 
1.04 (0.71 – 
1.53) 
0.53 (0.34 – 
0.83)** 
1.18 (1.08 – 
1.30)*** 
0.97 (0.71 – 
1.33) 
≥2 (n=7004) 1.27 (1.15 – 
1.40)*** 
1.17 (1.06 – 
1.30)** 
1.20 (1.08 – 
1.34)** 
0.83 (0.62 – 
1.10) 
0.88 (0.57 – 
1.37) 
0.82 (0.60 – 
1.13) 
1.30 (1.18 – 
1.43)*** 
1.06 (0.78 – 
1.45) 
AD, Alzhiemer’s disease; MixedD, mixed dementia; VaD, vascular dementia; DLB, dementia with Lewy bodies; FTD, frontotemporal 
dementia; PDD, Parkinson’s disease dementia; HR, hazard ratio; CI, confidence interval 
a. Adjusted for age, sex, Charlson Comorbidity Index, institutionalisation, living alone, home care, Mini-Mental State 
Examination score and use of antidementia drugs at baseline 
b. Additionally adjusted for dementia disorder 
*p <0.05 
**p<0.01 
***p<0.001 
  
SUPPLEMENTARY MATERIAL 
Supplementary Table 1. Anticholinergic Cognitive Burden scale drug scoring 
Score 1 Score 2 Score 3 
Alimemazine Amantadine Amitriptyline 
Alverine Belladonna Amoxapine 
Alprazolam Carbamazepine Atropine 
Aripiprazole Cyclobenzaprine Benztropine 
Atenolol Cyproheptadine Brompheniramine 
Bupropion Loxapine Carbinoxamine 
Captopril Meperidine Chlorpheniramine 
Chlorthalidone Methotrimeprazine Chlorpromazine 
Cimetidine  Molindone Clemastine 
Clidinium Nefopam Clomipramine 
Clorazepate Oxcarbazepine Clozapine 
Codeine Pimozide Darifenacin 
Colchicine  Desipramine 
Desloratadine  Dicyclomine 
Diazepam  Dimenhydrinate 
Digoxin  Diphenhydramine 
Dipyridamole  Doxepin 
Disopyramide  Fesoterodine 
Score 1 Score 2 Score 3 
Fentanyl  Flavoxate 
Furosemide  Hydroxyzine 
Fluvoxamine  Hyoscyamine 
Haloperidol  Imipramine 
Hydralazine  Meclizine 
Hydrocortisone  Methocarbamol 
Iloperidone  Nortriptyline 
Isosorbide  Olanzapine 
Levocetirizine  Orphenadrine 
Loperamide  Oxybutynin 
Loratadine  Paroxetine 
Metoprolol  Perphenazine 
Morphine  Promethazine 
Nifedipine  Propantheline 
Paliperidone  Propeverine 
Prednisone  Quetiapine 
Quinidine  Scopolamine 
Ranitidine  Solifenacin 
Risperidone  Thioridazine 
Theophylline  Tolterodine 
Score 1 Score 2 Score 3 
Trazodone  Trifluoperazine 
Triamterene  Trihexyphenidyl 
Venlafaxine  Trimipramine 
Warfarin  Trospium 
Adapted from: Aging Brain Care. Anticholinergic Cognitive Burden Scale—2012 Update. 
Available: www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf.  
(Accessed February 7 2018) 
  
Supplementary Table 2. Hazard ratios for the association between baseline ACB score and stroke and death in people with 
dementia  
 Composite stroke and 
death 
Death Stroke Ischemic stroke 
HRsa     
Continuous 1.02 (1.01 – 1.04)** 1.01 (1.00 – 1.03) 1.08 (1.05 – 1.12)*** 1.09 (1.05 – 1.13)*** 
Categorical     
0 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
1 1.03 (0.99 – 1.08) 1.04 (0.99 – 1.09) 1.09 (0.97 – 1.22) 1.14 (1.00 – 1.30)* 
≥2 1.11 (1.11 – 1.16)*** 1.08 (1.02 – 1.13)** 1.36 (1.21 – 1.53)*** 1.37 (1.20 – 1.56)*** 
c. Adjusted for age, sex, Charlson Comorbidity Index, institutionalisation, living alone, home care, Mini-Mental State 
Examination score and use of antidementia drugs at baseline 
d. Subdistribution hazard ratio 
*p <0.05 
**p<0.01 
***p<0.001 
  
Supplementary Table 3. Association between baseline ACB scores and composite of stroke and death by dementia disorder  
 AD 
N = 13269 
MixedD 
N = 7235  
VaD 
N = 5967  
DLB 
N = 879 
FTD 
N = 639 
PDD 
N = 601 
Unspecified 
N = 9531 
Other 
N = 986 
HRsa         
Continuous 1.03 (0.99 – 
1.06) 
1.02 (0.98 – 
1.05) 
1.02 (0.99 – 
1.06) 
0.95 (0.87 – 
1.04) 
1.04 (0.93 – 
1.17) 
1.03 (0.95 – 
1.11) 
1.03 (1.00 – 
1.06) 
1.10 (1.00 – 
1.21)* 
Categorical         
0 1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1 1.09 (1.00 – 
1.19) 
0.92 (0.78 – 
1.02) 
1.08 (0.97 – 
1.21) 
1.11 (0.84 – 
1.46) 
1.19 (0.80 – 
1.78) 
0.80 (0.53 – 
1.20) 
1.05 (0.95 – 
1.15) 
0.97 (0.71 – 
1.34) 
≥2 1.11 (1.00 – 
1.23)* 
1.08 (0.97 – 
1.20) 
1.06 (0.95 – 
1.19) 
0.83 (0.62 – 
1.11) 
1.44 (0.92 – 
2.26) 
1.02 (0.75 – 
1.39) 
1.21 (1.09 – 
1.33)*** 
1.17 (0.84 – 
1.63) 
AD, Alzhiemer’s disease; MixedD, mixed dementia; VaD, vascular dementia; DLB, dementia with Lewy bodies; FTD, frontotemporal 
dementia; PDD, Parkinson’s disease dementia; HR, hazard ratio; CI, confidence interval 
c. Adjusted for age, sex, Charlson Comorbidity Index, institutionalisation, living alone, home care, Mini-Mental State 
Examination score and use of antidementia drugs at baseline 
d. Additionally adjusted for dementia disorder 
*p <0.05 
**p<0.01 
***p<0.001 
 
 
 
